Technology including intellectual property and knowhow, developed by the UK Gene Therapy Consortium, made up of researchers at Imperial College London, the University of Oxford and Edinburgh University has been licensed to Boehringer Ingelheim in a continuation of a licence agreement first announced in 2018.
Accelerated development of a potential treatment for cystic fibrosis
Sectors: Medical research, Pharmaceuticals
Red blood cell-derived vesicles (RBCVs) for use in targeted delivery of thrombolytic drugs to blood clots. Find out more
A novel nanomedicine platform technology using biocompatible and biodegradable nanovesicles as carriers for a variety of clot-lysing thrombolytics Find out more
The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is one of the partners in a licensing agreement with Boehringer Ingelheim. Find out more
Sign up for updates
Sign up for monthly technology alerts via email, and find other ways to connect with us.